NovoCure Limited (NVCR) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $17.71 (+0.63%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jul 24, 2025 | Larry Biegelsen | Wells Fargo | $14.50 | -18.1% |
| Dec 2, 2024 | Vijay Kumar | Evercore ISI | $30.00 | +69.4% |
| Oct 16, 2024 | Emily Bodnar | H.C. Wainwright | $30.00 | +69.4% |
| Jul 26, 2024 | Emily Bodnar | H.C. Wainwright | $24.00 | +35.5% |
| May 3, 2024 | Emily Bodnar | H.C. Wainwright | $22.00 | +24.2% |
| May 2, 2024 | Vijay Kumar | Evercore ISI | $14.50 | -18.1% |
| Apr 10, 2024 | Jason Bednar | Piper Sandler | $28.00 | +58.1% |
| Apr 3, 2024 | Larry Biegelsen | Wells Fargo | $42.00 | +137.2% |
| Jan 5, 2023 | Emily Bodnar | H.C. Wainwright | $140.00 | +690.5% |
| May 16, 2022 | Emily Bodnar | H.C. Wainwright | $115.00 | +549.4% |
| Feb 8, 2022 | Jason Wittes | Loop Capital Markets | $200.00 | +1029.3% |
Top Analysts Covering NVCR
NVCR vs Sector & Market
| Metric | NVCR | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.43 | 2.24 | 2.41 |
| Analyst Count | 7 | 8 | 19 |
| Target Upside | +87.8% | +11474.9% | +17.1% |
| P/E Ratio | -9.92 | 4.03 | 31.98 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $165M | $170M | $175M | 5 |
| 2026-09-30 | $171M | $176M | $181M | 2 |
| 2026-12-31 | $175M | $180M | $186M | 2 |
| 2027-03-31 | $175M | $180M | $185M | 2 |
| 2027-06-30 | $179M | $184M | $190M | 2 |
| 2027-09-30 | $186M | $191M | $197M | 2 |
| 2027-12-31 | $190M | $196M | $202M | 2 |
| 2028-12-31 | $871M | $916M | $997M | 4 |
| 2029-12-31 | $1.45B | $1.52B | $1.66B | 3 |
| 2030-12-31 | $1.75B | $1.84B | $2.00B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.47 | $-0.37 | $-0.28 | 5 |
| 2026-09-30 | $-0.35 | $-0.34 | $-0.32 | 1 |
| 2026-12-31 | $-0.33 | $-0.32 | $-0.31 | 1 |
| 2027-03-31 | $-0.34 | $-0.32 | $-0.31 | 1 |
| 2027-06-30 | $-0.32 | $-0.31 | $-0.29 | 1 |
| 2027-09-30 | $-0.28 | $-0.27 | $-0.26 | 1 |
| 2027-12-31 | $-0.28 | $-0.27 | $-0.26 | 1 |
| 2028-12-31 | $-0.50 | $-0.41 | $-0.37 | 3 |
| 2029-12-31 | $2.30 | $2.45 | $2.73 | 1 |
| 2030-12-31 | $4.49 | $4.79 | $5.35 | 1 |
Frequently Asked Questions
What is the analyst consensus for NVCR?
The consensus among 7 analysts covering NovoCure Limited (NVCR) is Buy with an average price target of $33.50.
What is the highest price target for NVCR?
The highest price target for NVCR is $200.00, set by Jason Wittes at Loop Capital Markets on 2022-02-08.
What is the lowest price target for NVCR?
The lowest price target for NVCR is $14.50, set by Vijay Kumar at Evercore ISI on 2024-05-02.
How many analysts cover NVCR?
7 analysts have issued ratings for NovoCure Limited in the past 12 months.
Is NVCR a buy or sell right now?
Based on 7 analyst ratings, NVCR has a consensus rating of Buy (2.43/5) with a +87.8% upside to the consensus target of $33.50.
What are the earnings estimates for NVCR?
Analysts estimate NVCR will report EPS of $-0.37 for the period ending 2026-06-30, with revenue estimated at $170M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.